Curaleaf defends bid for Aurora, reiterates offer as “best path” for shareholders
Cash flow comparison
Curaleaf contrasts its operating cash generation with Aurora’s negative operating cash flow of C$4.4 million in the June quarter.
Curaleaf presses Aurora bid
Curaleaf is pressing its bid for Aurora Cannabis, calling it the best route to value creation for Aurora shareholders.
Dilution and capital raising
Curaleaf highlights Aurora dilution of about 31% since September 2020, tied to US$398 million of equity issuance.
Offer terms and valuation arguments
The offer was pitched as a 45% premium to Aurora’s unaffected price, with an exchange-value cap of US$5 per share.
Curaleaf disputes Aurora’s valuation objections, citing Aurora ATM sales at average prices of US$3.57 and US$3.09.
